# AM Policy Update: March 15, 2026

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/
> **Published:** 2026-03-15T22:08:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:07:04-04:00
> **Clinical Summary:** Explore the latest DEA scheduling cannabis policy updates from March 15, 2026, including controlled substances regulations impacting cannabis medicine.

---

AM Policy UpdateMarch 15, 2026. 20 regulatory items from Federal Register, regulations.gov, and regulatory RSS feeds.
Score 85Federal Register

[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)

The DEA temporarily placed bromazolam, a benzodiazepine analog, in Schedule I due to abuse potential, restricting its availability and research applications in controlled substance regulations.

[Read more →](https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0011)

The DEA placed three synthetic opioids (butonitazene, flunitazene, and metodesnitazene) in Schedule I, establishing their classification as drugs with no accepted medical use and high abuse potential.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0011)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0013)

The DEA placed ethylphenidate, a synthetic stimulant, into Schedule I, establishing it as a controlled substance with no accepted medical use, relevant to cannabis medicine’s regulatory framework for scheduling psychoactive compounds.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0013)Score 85Regulations.gov

[Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2024-0118-0001)

The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, restricting their legal availability, though these synthetic opioids have limited direct relevance to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) regulation.

[Read more →](https://www.regulations.gov/document/DEA-2024-0118-0001)Score 85Regulations.gov

[Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425](https://www.regulations.gov/document/DEA-2024-0112-0001)

# Regulatory Summary

DEA registration (2024-20085) permits an entity to import controlled biopharmaceuticals, including cannabis-derived medicinal products, for authorized research, manufacturing, or distribution purposes under federal oversight.

[Read more →](https://www.regulations.gov/document/DEA-2024-0112-0001)Score 85Regulations.gov

[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://www.regulations.gov/document/DEA-2023-0147-0003)

The DEA temporarily placed synthetic opioids N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, restricting their availability; not directly relevant to cannabis medicine regulation.

[Read more →](https://www.regulations.gov/document/DEA-2023-0147-0003)Score 85Regulations.gov

[Schedules of Controlled Substances: Rescheduling of Marijuana](https://www.regulations.gov/document/DEA-2024-0059-0001)

# Regulatory Summary

The DEA rescheduled marijuana to a lower controlled substance category, potentially expanding legal [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) and patient access while maintaining federal restrictions.

[Read more →](https://www.regulations.gov/document/DEA-2024-0059-0001)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0006)

The DEA placed three synthetic opioids (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) into Schedule I, restricting their availability; this action is minimally relevant to cannabis medicine regulation.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0006)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0007)

The DEA placed three synthetic opioids (butonitazene, flunitazene, and metodesnitazene) into Schedule I, restricting their availability and establishing no accepted medical use—relevant to cannabis medicine as a comparative regulatory precedent.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0007)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I](https://www.regulations.gov/document/DEA-2024-0026-0001)

# Regulatory Summary

The DEA placed 2-Methyl AP-237, a synthetic opioid analog, into Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis medicine policy as part of broader drug scheduling frameworks.

[Read more →](https://www.regulations.gov/document/DEA-2024-0026-0001)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I](https://www.regulations.gov/document/DEA-2023-0168-0001)

The DEA placed two synthetic amphetamine derivatives (2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine) into Schedule I, establishing they have high abuse potential and no accepted medical use.

[Read more →](https://www.regulations.gov/document/DEA-2023-0168-0001)Score 85Regulations.gov

[Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I](https://www.regulations.gov/document/DEA-2023-0049-0004)

The DEA temporarily placed six synthetic cannabinoids into Schedule I, classifying them as controlled substances with no accepted medical use, restricting their availability for [cannabis medicine research](https://cedclinic.com/cannabinoids-neuromuscular-communication-benefits/) and clinical applications.

[Read more →](https://www.regulations.gov/document/DEA-2023-0049-0004)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I](https://www.regulations.gov/document/DEA-2023-0129-0001)

The DEA placed ethylphenidate, a synthetic stimulant, in Schedule I, establishing it as having no accepted medical use; relevant to cannabis policy as a precedent for scheduling psychoactive substances.

[Read more →](https://www.regulations.gov/document/DEA-2023-0129-0001)Score 85Regulations.gov

[Schedules of Controlled Substances: Placement of Metonitazene in Schedule I](https://www.regulations.gov/document/DEA-2021-0031-0005)

The DEA scheduled metonitazene, a synthetic opioid, as a Schedule I controlled substance, establishing it as having high abuse potential and no accepted medical use, distinct from cannabis medicine regulations.

[Read more →](https://www.regulations.gov/document/DEA-2021-0031-0005)Score 85Regulations.gov

[Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I](https://www.regulations.gov/document/DEA-2022-0145-0004)

# Regulatory Summary

The DEA temporarily placed five benzodiazepine analogs (etizolam, flualprazolam, clonazolam, flubromazolam, diclazepam) in Schedule I, restricting their legal availability and relevance to cannabis medicine research involving controlled substance interactions.

[Read more →](https://www.regulations.gov/document/DEA-2022-0145-0004)Score 85Regulations.gov

[Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224](https://www.regulations.gov/document/DEA-2023-0096-0001)

# Regulatory Summary

A biopharmaceutical research company’s DEA application to import controlled substances, including cannabis-derived materials, for medical research and development purposes.

[Read more →](https://www.regulations.gov/document/DEA-2023-0096-0001)Score 70Regulations.gov

[Importer of Controlled-Bright Green(2024-20083)DEA1426](https://www.regulations.gov/document/DEA-2024-0111-0001)

# Regulatory Summary

DEA registration 2024-20083 authorizes an importer to legally procure controlled cannabis substances for medical research, manufacturing, or distribution purposes under federal drug enforcement regulations.

[Read more →](https://www.regulations.gov/document/DEA-2024-0111-0001)Score 70Regulations.gov

[Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429](https://www.regulations.gov/document/DEA-2024-0110-0001)

# Regulatory Summary

DEA registration 2024-20082 permits Cambridge Isotope Laboratories to import controlled cannabis substances for research and analytical purposes, supporting legitimate scientific investigation of cannabis-derived medicines.

[Read more →](https://www.regulations.gov/document/DEA-2024-0110-0001)Score 70Regulations.gov

[Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.](https://www.regulations.gov/document/CMS-2024-0256-0045)

CMS updates 2025 Medicare/Medicaid payment policies and Part B coverage, potentially affecting reimbursement frameworks for cannabis-derived medical products and practitioner services under federal healthcare programs.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0045)Score 70Regulations.gov

[Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)](https://www.regulations.gov/document/CMS-2024-0256-0001)

# Regulatory Summary

CMS proposed 2025 Medicare Part B payment policies and coverage updates; cannabis remains federally non-covered under Medicare/Medicaid, limiting reimbursement opportunities for cannabis-based medicinal products.

[Read more →](https://www.regulations.gov/document/CMS-2024-0256-0001)

Clinical Commentary

 Dr. Caplan’s Take
 # Clinical Reflection

Among these 20 policy items, only item 7 directly addresses cannabis scheduling, while the remaining 19 focus on synthetic opioids, benzodiazepines, stimulants, and novel psychoactive substances, signaling that DEA enforcement priorities remain concentrated on more acutely dangerous drug classes rather than cannabis rescheduling implementation. This regulatory landscape suggests that even if cannabis rescheduling proceeds, practitioners like myself should anticipate a transitional period where cannabis medicine operates within an evolving legal framework while the broader controlled substances infrastructure continues targeting substances with higher overdose mortality and addiction potential. The relative absence of cannabis-specific enforcement items in this digest may reflect either bureaucratic focus elsewhere or potential movement toward cannabis policy normalization, though clinical practice should remain grounded in state law compliance and evidence-based prescribing standards regardless

Drug SchedulingControlled SubstancesDEA RegulationsSynthetic DrugsSubstance Abuse Policy

 

💬 Join the Conversation

 

Have a question about how this applies to your situation?
 [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

 

Want to discuss this topic with other patients and caregivers?
 [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Policy+Digest+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Policy+Digest+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/)

Review the regulatory changes and DEA scheduling updates from March 11, 2026, for a broader understanding of recent cannabis policy developments.

[Read More](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/)

[AM Policy Update: March 16, 2026](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/)

Stay informed on the latest DEA scheduling and cannabis policy updates from March 16, 2026, with detailed regulatory insights.

[Explore Update](https://cedclinic.com/dea-scheduling-cannabis-rescheduling-march-16-2026/)

[AM Policy Update: March 17, 2026](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/)

Get the most recent information on cannabis scheduling and controlled substances regulations from the March 17, 2026 policy update.

[Learn More](https://cedclinic.com/dea-synthetic-opioids-schedule-i-march-17-2026/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).